Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1949
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbeyakoon, Chathuri-
dc.contributor.authorHarrop, Sean-
dc.contributor.authorYannakou, Costas-
dc.contributor.authorPrince, Miles-
dc.contributor.othervan der Weyden, Carrie-
dc.contributor.otherKhot, Amit-
dc.contributor.otherDickinson, Michael-
dc.date.accessioned2021-01-19T02:02:50Z-
dc.date.available2021-01-19T02:02:50Z-
dc.date.issued2020-10-
dc.identifier.citationCancers 2020, 12(11), 3125en_US
dc.identifier.issn2072-6694;en_US
dc.identifier.urihttp://hdl.handle.net/11434/1949-
dc.description.abstractPeripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory "one-size-fits-all" approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.en_US
dc.publisherMDPIen_US
dc.subjectPeripheral T-cell Lymphomasen_US
dc.subjectPTCLen_US
dc.subjectHaematopoietic Stem Cell Transplantationen_US
dc.subjectBone Marrow Transplanten_US
dc.subjectAutologous Stem Cell Transplantationen_US
dc.subjectAllogeneic Stem Cell Transplantationen_US
dc.subjectCancer Services Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleRole of haematopoietic stem cell transplantation in peripheral T cell lymphoma.en_US
dc.typeJournal Articleen_US
dc.identifier.doihttps://doi.org/10.3390/cancers12113125en_US
dc.identifier.journaltitleCancersen_US
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/33114606/en_US
dc.description.affiliatesPeter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.en_US
dc.description.affiliatesSir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3000, Australia.en_US
dc.description.affiliatesRoyal Melbourne Hospital, Melbourne, Victoria 3052, Australia.en_US
dc.type.studyortrialReviewen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services

Files in This Item:
File Description SizeFormat  
cancers-12-03125.pdf640.52 kBAdobe PDFThumbnail
View/Open


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.